Reducing long-tail claims through medication governance

How medication review and deprescribing accelerate claim closure and eliminate costly claim extensions

Published: 3 April 2026 | Updated: 3 April 2026

The hidden cost of long-tail claims

Long-tail claims are the claims that refuse to close. They extend beyond expected recovery timelines, accumulate unexpected costs, and consume disproportionate claims management resources. For your portfolio, long-tail claims represent a financial and operational burden: higher loss ratios, extended exposure, and claims staff time diverted from newer cases.

While injury severity drives some claim duration, medication management is a critical but often overlooked determinant of how quickly claims close. Claims with optimised medication regimens close faster and more reliably than claims with escalating or poorly managed medications. Understanding and managing medication as a claim closure lever transforms your approach to long-tail claim resolution.

Why medications extend claims

Several medication-related factors contribute to claim extension:

Medication dependence preventing closure

Claimants on long-term sedating medications, pain medications with dependence liability, or benzodiazepines cannot safely cease these medications abruptly. If medication reduction is necessary for closure but has not been planned and supported, the claim extends indefinitely. Claimants remain medicated but not recovered, in a holding pattern where neither further treatment nor closure is appropriate.

Medication-induced functional impairment

Medications prescribed early in recovery that served a purpose may later impair return-to-work functioning. Sedating antidepressants, pain medications, and cognitive-affecting medications prevent participation in workplace retraining or return-to-work activities. The claim stalls because functional recovery cannot progress while the claimant is impaired by medication side effects.

Polypharmacy complicating care

Claimants on five, six, or seven medications without clear coordination develop side effects, drug interactions, and general cognitive decline. These complications create new medical issues requiring investigation and treatment. Each new complication extends the claim. The claim becomes about managing medication complications rather than recovering from the original injury.

Medication cost barriers to closure

As claims approach closure, ongoing medication costs loom large in closure negotiations. If your claimant requires permanent medications, medication costs become a central closure issue. Claims extending primarily to manage medication cost negotiations represent lost opportunity for earlier resolution.

Prescription of inappropriate medications

Some medications prescribed for injury-related conditions lack clear efficacy or are prescribed at doses higher than evidence supports. These medications contribute to costs and side effects but not to functional recovery. The claim cannot close because functional recovery remains stalled despite ongoing treatment.

Identifying long-tail medication risks

Early identification of claims at risk of medication-driven extension allows proactive intervention. Screen your claims for these warning signs:

Strategic medication review in long-tail claims

For claims extending beyond expected closure timelines, medication review becomes essential. Unlike routine claims, long-tail medication reviews focus specifically on closure enablement:

Deprescribing as a closure strategy

Deprescribing is not an optional refinement in long-tail claims; it is a closure requirement. Many claims cannot close until medications are reduced. The key is planning deprescribing early and implementing it systematically:

Early-stage deprescribing (first 6-12 months)

Establish reduction plans for medications unlikely to be needed long-term: acute pain medications, sedatives for initial sleep disturbance, short-term antidepressants. Build reduction into the original prescribing decision. "This benzodiazepine is for initial sleep support for 8-12 weeks, followed by gradual cessation."

Mid-term deprescribing (12-24 months)

As rehabilitation progresses, reduce medications no longer supporting functional goals. Sedating antidepressants limiting work retraining should be deprescribed even if some mood support remains. Pain medications limiting exercise participation should be reduced to enable more effective rehabilitation.

Closure-phase deprescribing (24+ months)

For claims approaching closure, deprescribing becomes essential. This is the phase where long-tail extension often occurs. Work with the claimant's medical team on cessation of injury-specific medications, establishing permanent medication arrangements, and resolving medication cost liability.

Practical deprescribing approaches for long-tail claims

The gradual reduction method

Reduce medications slowly over 8-16 weeks. This method minimises withdrawal effects and allows monitoring of claimant response. Establish clear targets: "Reduce by 25% every 4 weeks until cessation." Document progress and adjust if withdrawal symptoms emerge.

The alternate-day method

Useful for some medications: gradually reduce dosing frequency before reducing dose. "Take every second day for 2 weeks, then every third day for 2 weeks, then cease." This approach works well for some sedatives and antidepressants.

The switch-and-reduce method

If medication must change but complete cessation is not immediate, switch to a shorter-acting or lower-cost equivalent, then reduce that medication. This maintains symptom control while reducing cost and side effects.

The structured withdrawal plan

For high-risk medications (benzodiazepines, opioids), provide written withdrawal protocols with specific milestones, symptom management strategies, and emergency contact information. Clear structure increases adherence and reduces safety concerns.

Overcoming deprescribing obstacles in long-tail claims

Claimant resistance to medication change

Challenge: Your claimant has been on medications for years and fears what happens without them.

Strategy: Reframe deprescribing as closure enablement, not abandonment. "Reducing your sedating medication will allow you to focus and retrain. Once you're back at work and stable, we can move to claim closure." Link medication reduction to claimant goals, not just insurer interests.

Medical provider reluctance

Challenge: The treating provider resists medication reduction due to fear of symptom return or claimant complaint.

Strategy: Provide evidence and a structured plan. Request a specific deprescribing protocol with milestones and monitoring. Engage specialist pharmacy support to convince the provider of safety.

Withdrawal symptoms complicating reduction

Challenge: Deprescribing attempts produce withdrawal symptoms, derailing the plan.

Strategy: Slow the reduction schedule, reduce dose increments, or employ bridging medications. Address withdrawal symptoms proactively rather than abandoning the deprescribing plan.

Medication cost disputes at closure

Challenge: Your claimant requires ongoing medications, creating liability questions at closure.

Strategy: Conduct medication review early to clarify which medications are injury-related and require liability continuation. Dispute resolution is easier with clear medication documentation.

Measuring deprescribing success

Track these metrics to assess whether your medication governance strategy is enabling claim closure:

• Reduction in average medications per claimant over time
• Increase in claimants achieving targeted deprescribing milestones
• Time from deprescribing initiation to medication reduction or cessation
• Correlation between deprescribing and improved functional capacity
• Time from deprescribing to claim closure or return-to-work achievement
• Reduction in claim duration for closed claims where deprescribing occurred versus without
• Cost savings from medication reduction and claim closure acceleration

Building a medication governance culture for claim closure

Transforming your approach to long-tail claims requires embedding medication governance into your standard closure strategy. This means:

• Assessing medication appropriateness at regular claim reviews
• Planning deprescribing early rather than addressing at closure
• Engaging specialist medication review when functional plateaus occur
• Treating medication reduction as a key closure milestone
• Monitoring deprescribing progress as a core claims management metric
• Building deprescribing timelines into closure plans

Your pathway to reducing long-tail claims

Long-tail claims are costly and frustrating, but many are medication-driven and therefore manageable. By implementing systematic medication review, establishing clear deprescribing plans, and linking medication reduction to closure, you transform stalled claims into resolved ones. The opportunity is significant: each long-tail claim you close through medication optimisation improves portfolio economics and frees management capacity for newer cases.